{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-030460","form_type":"8-K/A","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.969706+00:00","generated_at":"2026-06-08T14:25:27.165455+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vistagen receives $1.5M from Fuji Pharma for exclusive PH80 negotiation in Japan","bullets":["Received $1.5M non-refundable payment from Fuji Pharma for exclusive negotiation rights to license PH80 in Japan.","PH80 is a non-systemic, hormone-free pherine nasal spray for acute treatment of moderate-to-severe hot flashes due to menopause.","Purchase price credited against signing fee if definitive license agreement reached.","Neither party obligated to enter definitive agreement; negotiations may be terminated after exclusive period."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-030460","json":"https://secwatch.observer/filing/0001437749-23-030460.json","markdown":"https://secwatch.observer/filing/0001437749-23-030460.md","text":"https://secwatch.observer/filing/0001437749-23-030460.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923030460/0001437749-23-030460-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923030460/vtgn20231106_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T14:25:27.165455+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}